Clinical Trials Directory

Trials / Unknown

UnknownNCT05339607

Endoscopic Resection of Papillary Adenomas; a Novel Treatment Algorithm to Prevent Recurrence - a Pilot-study (ERASE-pilot)

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Recurrence after endoscopic papillectomy is described in up to 33% of the cases (range 12-33%). This leads to re-interventions, a cumulative risk of adverse events, and the need for long-term follow-up. Recurrences most likely originate from either the biliary orifice or lateral resection margins. Ablative methods such as radiofrequency ablation (RFA) and thermal ablation by cystotome inside the bile duct have been described to treat intraductal extension of which the use of a cystotome seems to have a more favorable safety profile. However, no studies focusing on the preventive use of these ablative methods in patient with papillary adenomas have been performed. It is hypothesized that the curative resection rate can be increased and recurrence prevented by using a combination of snare tip soft coagulation (STSC) of the resection margins and thermal ablation by cystotome of the biliary orifice in patients with and without the suggestion of intraductal extension. Therefore, aim of this study is to assess the safety and feasibility of endoscopic papillectomy combined with thermal ablation of the biliary orifice by cystotome and STSC of the lateral resection margins.

Conditions

Interventions

TypeNameDescription
OTHERThermal ablation of resection margins by STSC and biliary orifice by cystotome.Patients who are eligible will undergo thermal ablation of the resection margins.

Timeline

Start date
2022-05-05
Primary completion
2023-12-31
Completion
2023-12-31
First posted
2022-04-21
Last updated
2023-02-02

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT05339607. Inclusion in this directory is not an endorsement.